case_images: PMC10906999_01
case_images: Case report timeline.
case_images: cro-2024-0017-0001-535743_F01.jpg
case_images: PMC10906999_01_cro-2024-0017-0001-535743_F01.jpg
case_images: F1
case_images: A 65-year-old AA and Native American woman was diagnosed with right breast ER negative, PR negative, HER-2 equivocal by immunohistochemistry, and positive by fluorescence in situ hybridization (ratio: 3.1) invasive carcinoma pT2N0 in 2013 (Fig. 1). She began pembrolizumab on 29 December 2021 (8 years post-initial diagnosis) (Fig. 1).
case_images: Initial staging 18FDG-PET scan of the patient showing region of 18FDG uptake in the right lung, right breast, and axilla. PET, positron emission tomography.
case_images: cro-2024-0017-0001-535743_F02.jpg
case_images: PMC10906999_01_cro-2024-0017-0001-535743_F02.jpg
case_images: F2
case_images: Positron emission tomography/CT demonstrated a 1.4-cm FDG-avid pulmonary nodule and FDG-avid nodular soft tissue thickening in the right breast and axilla (Fig. 2). She responded exceptionally to pembrolizumab with a reduced disease burden (Fig. 2, 3).
case_images: Staging scan from December 2022, 18FDG-PET scan of the patient showing region of 18FDG uptake in the right breast and axilla, minus left lung lesion. PET, positron emission tomography.
case_images: cro-2024-0017-0001-535743_F03.jpg
case_images: PMC10906999_01_cro-2024-0017-0001-535743_F03.jpg
case_images: F3
case_images: She responded exceptionally to pembrolizumab with a reduced disease burden (Fig. 2, 3). The metastatic pulmonary lesions demonstrated a drastically reduced 18F-FDG uptake, stabilizing for 14 months (Fig. 3).